-
Morse Martinsen posted an update 6 months ago
The aim of the study was to increase the participants’ satisfaction with the unilateral peripheral vestibular pathology, in addition to the exercise program, with galvanic vestibular stimulation (GVS).
Participants were divided into 2 groups study group (41 subjects) and control group (32 subjects). SBE-β-CD cell line Participants who underwent videonystagmography and sensory organization testing, which were objective test methods at the beginning, were invited to check in every week for 6 weeks to perform GVS and/or exercise in the exercise program. Objective tests were repeated at the end of the sixth week. A visual analog scale (VAS) was administered every week.
Unilateral weakness, balance scores 4, 5, 6; visual, vestibular, preference and strategy scores 5, 6; center of gravity 1, 2, 3, 4, 5, 6; composite scores were different between the groups after rehabilitation (p < 0.05). In terms of VAS, the study group began to feel better at the end of the first week than the control group (p < 0.01).
It was found that the study group benefited both from an objective and a subjective point of view more than participants in the control group.
It was found that the study group benefited both from an objective and a subjective point of view more than participants in the control group.
Rivastigmine is an acetylcholine esterase inhibitor which is commonly used as therapy for dementia in Alzheimer’s disease and Parkinson’s disease (PD). Recently, a randomized controlled trial demonstrated a positive effect of rivastigmine on gait function in nondemented PD patients. Disturbed gait is a shared hallmark of PD and ataxias.
We hypothesized that the effect of rivastigmine could be translated to spinocerebellar ataxia (SCA) improving gait function.
Five patients with SCA type 3 were treated with transdermal rivastigmine for 8 weeks. The patients were monitored using the Scale for the Assessment and Rating of Ataxia (SARA) and an electronic walkway system (GAITRite®).
Gait function was not changed by treatment, but 4 patients who continued treatment for 8 weeks showed improved coordination of extremities. The SARA sum score, which was 7.6 ± 2.2 at baseline, had dropped by 1.5 ± 1.9 after 4 weeks and by 2.1 ± 1.4 after 8 weeks.
Contrary to our hypothesis, we observed no improvement of gait parameters as assessed by SARA and GAIT-Rite®, but coordination abilities were improved. Rivastigmine was well tolerated, but known side effects of rivastigmine, such as deterioration of asthma, may appear. Further trials in larger cohorts are needed to confirm our findings.
Contrary to our hypothesis, we observed no improvement of gait parameters as assessed by SARA and GAIT-Rite®, but coordination abilities were improved. Rivastigmine was well tolerated, but known side effects of rivastigmine, such as deterioration of asthma, may appear. Further trials in larger cohorts are needed to confirm our findings.We performed Monte Carlo simulations in order to determine, by means of microdosimetry calculations, tumour control probability (TCP) curves for treatments with225Ac-PSMA of metastatic castration resistant prostate cancer (mCRPC). Realistic values of cell radiosensitivity, nucleus size and lesion size were used for calculations. As the cell radiosensitivity decreased, the nucleus size decreased and the lesion size increased, the absorbed dose to reach a given TCP increased. The highest variations occurred with regard to the cell radiosensitivity. For the Monte Carlo simulations, in order to address a non-uniform PSMA expression, different225Ac-PSMA distributions were considered. The effect of these different PSMA distributions resulted in small variations in the TCP curves (maximum variation of 5%). Absorbed doses to reach a TCP of 0.9 for a uniform225Ac-PSMA distribution, considering a relative biological effectiveness (RBE) of 5, ranged between 35.0 Gy and 116.5 Gy. The lesion absorbed doses per administered activity reported in a study on treatments with225Ac-PSMA of mCRPC ranged between 1.3 Gy/MBq and 9.8 Gy/MBq for a RBE = 5. For a 70 kg-patient to whom 100 kBq/kg of225Ac-PSMA are administered, the range of lesion absorbed doses would be between 9.1 Gy and 68.6 Gy. Thus, for a single cycle of 100 kBq/kg, a number of lesions would not receive an absorbed dose high enough to reach a TCP of 0.9.Abstract:A novel three-dimensional (3D) microtubular NO2FET sensor has been fabricated from the two-dimensional (2D) reduced graphene oxide (rGO) nanosheets decorated with Ag nanoparticles, by applying the self-roll up technique. The electrical properties of 2D and 3D FET Ag NPs/rGO sensors have been investigated and compared. Finally, the performance of the 3D sensors has been demonstrated, where the preliminary results shown that our 3D FET Ag NPs/rGO NO2sensor exhibit a relative fast response (response time of 116 s) to 20 part per million (ppm) NO2with a response of 4.92 % at room temperature at zero bias voltage and 2 V source-drain bias voltage. Moreover, the characteristics of our 3D FET Ag NPs/rGO sensors, e.g. response, response and recovery times have been demonstrated to be tuned by adjusting the applied source-drain and gate biases. Compared to 2D geometry, our 3D geometry occupied less device area, but with the same sensing area. This study would provide a new way to optimize sensing devices performance, and promote its developments for miniaturized and integrated gas sensing applications for indoor health and safety detections, outdoor environmental monitoring, industrial pollution monitoring and beyond.Graphene nanoribbon is an attractive material for nano-electronic devices, as their electrical transport performance can be controlled by their edge structures. However, in most cases, the electrical transport has been investigated only for graphene nanoribbons fabricated on a substrate, which hinders the appearance of intrinsic electrical transport due to screening effects. In this study, we developed special devices based on silicon chips for transmission electron microscopy to observe a monolayer graphene nanoribbon suspended between two gold electrodes. Moreover, with the development of an in-situ transmission electron microscopy holder, the current-voltage characteristics were achieved simultaneously with observing and modifying the structure. We found that the current-voltage characteristics differed between 1.5 nm-wide graphene nanoribbons with armchair and zigzag edge structures. The energy gap of the zigzag edge was more than two-fold larger than that of the armchair edge and exhibited an abrupt jump above a critical bias voltage in the differential conductance curve.